Evidence mapPaperPMID 41601660Full record

ReviewFrontiers in immunology2025

Natural killer cell-based senotherapy: a promising strategy for healthy aging.

Tsutomu Nakazawa, Ryo Yamanishi, Takayuki Morimoto, Ryosuke Matusda

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tsutomu NakazawaGrandsoul Research Institute for Immunology, Inc., Utano, Uda, Nara,, Japan.
Ryo YamanishiSocial Welfare Organization HIRAKATA RYOIKUEN, Hirakata, Osaka, Japan.
Takayuki MorimotoDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
Ryosuke MatusdaDepartment of Neurosurgery, Nara Medical University, Shijocho, Kashihara, Nara, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most significant risk factors for diseases is aging. Interestingly, some organisms, such as naked mole-rats and most turtles, do not exhibit typical aging-like symptoms or increased mortality as they become older. These aspects indicate that aging is not necessarily an essential event for animal life and are avoidable. Overcoming aging would free humans from age-associated diseases (AADs) and prolong lifespans. Recent studies have demonstrated that one of the causes of age-related organ dysfunction is excessive chronic inflammation caused by the accumulation of senescent cells (SNCs) and their senescence-associated secretory phenotypes (SASPs). Therefore, the development of drugs and medication to remove SNCs is ongoing. Natural killer (NK) cells are integral components of the innate immune system that are critical for clearing SNCs. Beyond this direct function, NK cells also orchestrate innate and adaptive immunity responses to survey and eradicate these compromised cells. Consequently, preserving NK cell function throughout the aging process is paramount for mitigating AADs and promoting robust health in later life. Simultaneously, NK cell-based senotherapy presents compelling avenues for addressing the multifaceted challenges associated with SNC accumulation and aging. Recent investigations into adoptive NK cell-based senotherapy have demonstrated considerable promise in rejuvenating immunosenescence, facilitating SNC elimination. The accumulating evidence provides a promising proof-of-concept for adoptive NK cell-based senotherapy, indicating its potential as a development in longevity therapeutics.

Indexed as

AgingCellular SenescenceHealthy AgingKiller Cells, NaturalAnimalsHumansImmunity, InnateSenescence-Associated Secretory Phenotypeadoptive immunotherapyantiagingimmunotherapyNK cellsenescence

Identifiers

PMID41601660
PMCPMC12833471

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.